Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) that support the company's plans for an adaptive Phase 2 field study of TNX-4800, its long-acting anti-OspA monoclonal antibody candidate designed to prevent Lyme disease. This regulatory feedback marks a significant step forward in the development of a potential seasonal immunopreventative against a tick-borne illness that affects hundreds of thousands of people in the United States each year.
The planned randomized, placebo-controlled study is expected to enroll approximately 3,300 adults over two Lyme disease seasons to evaluate the prevention of Lyme disease through six months after dosing. The study design, which received FDA support, aims to assess the efficacy and safety of TNX-4800 in a real-world setting where Lyme disease is endemic. Manufacturing of the investigational product is on track for delivery to study sites in the first quarter of 2027, indicating that the company is moving forward with the necessary steps to initiate the trial.
TNX-4800 is being developed as a seasonal immunopreventative administered as two subcutaneous injections three months apart. This dosing regimen has the potential to provide protection throughout the U.S. Lyme disease season, which typically peaks in the summer months. If successful, TNX-4800 could offer a new option for individuals at high risk of Lyme disease, such as those living in or traveling to endemic areas.
The FDA's feedback is crucial as it validates the company's approach to studying the candidate. The adaptive design of the trial allows for modifications based on interim data, potentially increasing the efficiency of the study. The large sample size is expected to provide robust data on the efficacy of TNX-4800 in preventing Lyme disease, which is caused by Borrelia burgdorferi and transmitted by tick bites.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's recent approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) for fibromyalgia, the first new treatment for this condition in over 15 years, demonstrates its ability to bring innovative therapies to market. In addition to its CNS portfolio, Tonix is advancing immunology programs, including TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The progress with TNX-4800 is particularly noteworthy given the increasing incidence of Lyme disease in the United States. According to the Centers for Disease Control and Prevention, approximately 476,000 people are diagnosed and treated for Lyme disease each year. Current prevention methods, such as tick avoidance and early removal, are not always effective, and there is no vaccine approved for humans in the U.S. A long-acting monoclonal antibody that provides seasonal protection could significantly reduce the burden of this disease.
The FDA's support for the Phase 2 study is a positive indicator for the development of TNX-4800. The company plans to initiate the trial in 2027, and the results will be critical in determining whether to advance the candidate to Phase 3 trials. If successful, TNX-4800 could become a valuable tool in the fight against Lyme disease, offering a new layer of protection for at-risk populations.
For more information about Tonix Pharmaceuticals and its pipeline, visit the company's newsroom at https://ibn.fm/TNXP.
